A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
NCT ID: NCT03515785
Last Updated: 2018-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2018-12-31
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ph+ ALL Patients
Patients with Ph+ ALL being treated with Iclusig®.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures.
Exclusion Criteria
* Patients who are pregnant and/or breastfeeding.
* Concurrent treatment with another tyrosine kinase inhibitor for Ph+ALL.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Biosciences International Sàrl
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dieter Hoelzer, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Oncologikum Frankfurt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ihbt/Úhkt
Prague, , Czechia
University Hospital Amiens
Amiens, , France
University Hospital Angers
Angers, , France
University Hospital Bordeaux
Bordeaux, , France
University Hospital Grenoble
Grenoble, , France
University Hospital Lyon
Lyon, , France
University Cancer Institute Oncopole
Toulouse, , France
University Hospital Halle/Saale
Halle, , Germany
University Hospital Munich
Munich, , Germany
University Hospital Rostock
Rostock, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCB-DEMA-ALL-401
Identifier Type: -
Identifier Source: org_study_id